Canadian clinical-stage biotechnology company AmacaThera on Wednesday announced results from its Phase 1 clinical trial of AMT-143, an innovative, non-opioid anaesthetic, formulated with the company's patented AmacaGel platform, demonstrating sustained anaesthetic release out to 14 days.

AMT-143 is aimed at delivering extended, localised pain relief without the need for opioids, significantly reducing the risks related to opioid addiction and side effects to improve patient outcomes post-surgery.

Dr Mike Cooke, AmacaThera CEO and co-founder, said: "We are excited by the promise of these results as they show a substantial differentiation above and beyond the currently available products and herald a next generation of post-surgical pain relief alternatives. We look forward to advancing this important product into a Phase 2 study."

Paul Austin, lead investor of AmacaThera's recently completed Series A extension, added: "The progress shown in the Phase 1 study demonstrates the tremendous potential of AMT-143 to transform post-operative pain management. Based on these strong results, we are increasing our investment to accelerate its continuing development."